



ALZHEIMER’S DISEASE STATE OF PLAY
WITH FOCUS ON
SIMILARITIES BETWEEN MECHANISMS OF ACTION OF NE3107¹, XPRO², SIMUFILAM³ AND
COYA 301/302⁴

TABLE OF CONTENTS

1. Introduction 6

 1.1. The traditional approach for the treatment of Alzheimer’s disease 6

 1.1.1. Introduction 6

 1.1.2. The early onset of neurodegenerative diseases 6

 1.1.3. Historical trial failures 7

 1.1.4. Traditional treatments: acetylcholinesterase inhibitors 8

 1.1.5. Latest developments: provisional/final approval of anti-amyloid antibodies 9

 1.2. What’s ahead: novel approaches 9

 1.2.1. Introduction: the future beyond anti-amyloid 9

 1.2.2. Apparent disconnection between scientific developments and investments 10

 1.2.3. Potential similarities between reported effect on cognition and mechanism of action of
 respective drug candidates 11

 1.2.4. Investor potential 11

2. Cumulative stressors: amyloid, tau, inflammation and metabolic dysregulation are implicated in
Alzheimer’s disease 13

 2.1. Introduction 13

 2.2. Amyloid 13

 2.3. Tau 15

 2.4. Inflammation as a more novel hallmark of neurodegenerative diseases 16

 2.5. The cumulative burden of stressors due to Western lifestyle, metabolic syndrome, toxins and
 viruses as probable cause of neurodegenerative diseases 17

 2.5.1. Introduction 17

 2.5.2. Early reported success through intense lifestyle and dietary changes 22

¹ Drug candidate of BioVie.
² Drug candidate of INmune Bio.
³ Drug candidate of Cassava Sciences.
⁴ Drug candidate of Coya Therapeutics.



3. Current treatments and anti-amyloid antibodies.....	24
3.1. Approved treatments until 2021	24
3.2. The advent of anti-amyloid antibodies.....	24
3.2.1. 2021: Aducanumab / Aduhelm	24
3.2.2. 2022: Lecanemab / Leqembi	25
3.2.3. 2023: Donanemab	27
3.2.4. The Alzheimer’s pipeline	28
3.2.5. Safety issues	30
3.3. Unmet medical needs.....	30
3.3.1. The need to act earlier in the development of the disease	31
3.3.2. Shortcomings of anti-amyloid antibodies.....	31
3.3.3. The need for further-reaching / personalized / combination therapies	31
3.3.4. The need for treatments of moderate and severe Alzheimer’s disease	31
4. Novel approaches for the treatment of Alzheimer’s disease focusing on inflammation and metabolic dysregulation.....	32
4.1. Introduction.....	32
4.2. Potential of NE3107, XPro, simufilam and Coya 301/302 to restore cognitive function.....	32
4.2.1. Introduction.....	33
4.3.2. BioVie – NE3107	33
4.3.3. INmune Bio - XPro	34
4.3.4. Cassava Sciences - simufilam.....	34
4.3.5 Coya Therapeutics – Coya 301/302	36
4.3.6 Side note: Athira Pharma’s ‘failed’ Phase 2 trial and ongoing Phase 2b/3 trial	38
5. BioVie’s NE3017’s	39
5.1. NE3107’s mechanism of action	39
5.2. Scientific background	42
5.3. Mechanistic similarities and differences	43
5.3.1. Activity through TLR4 and possibly CD14.....	43
5.3.2. Anti-inflammatory through inhibition of ERK and JNK.....	44
5.3.3. Selective inhibition of NF-kB signaling by NE3107 through TNFR1.....	44
5.3.4. Improved insulin receptor signaling involving IRS.....	47
5.3.5. Biomarkers.....	47
5.3.6. Potential to stabilize cognitive decline	48
5.3.7. Responder heterogeneity.....	48



5.3.8 Systemic normalization / anti-aging	48
5.3.9. Safety	49
5.3.10. Fast onset	49
5.3.11. No infusion	49
5.3.12. Dual mechanism of action	49
6. INmune Bio's XPro	50
6.1. XPro's mechanism of action	50
6.2. Scientific background	51
6.3. Mechanistic similarities and differences	52
6.3.1. Anti-inflammatory activity through TLR4	52
6.3.2. Anti-inflammatory activity through inhibition of ERK and JNK	53
6.3.3. Anti-inflammatory activity through inhibition of NF-kB signaling.....	53
6.3.4. Improved insulin receptor signaling	53
6.3.5. Biomarkers.....	54
6.3.6. Potential to stabilize cognitive decline	56
6.3.7. Responder heterogeneity	57
6.3.8 Systemic normalization / homeostasis / anti-aging.....	57
6.3.9. Safety.....	58
6.3.10. Fast onset	58
6.3.11. No infusion	58
6.3.12. Potentially dual mechanism of action	59
7. Cassava Sciences' simufilam	60
7.1. Simufilam's mechanism of action.....	60
7.2. Scientific background	61
7.3. Mechanistic similarities and differences	61
7.3.1. Anti-inflammatory activity through TLR4 and CD14.....	62
7.3.2. Anti-inflammatory activity through inhibition of ERK1 and JNK	62
7.3.3. Possible anti-inflammatory activity through inhibition of NF-kB	63
7.3.4. Improved insulin receptor signaling involving IRS1	64
7.3.5. Biomarkers.....	66
7.3.6. Potential to stabilize cognitive decline, excluding moderate patient population	66
7.3.7. Responder heterogeneity	68
7.3.8. Systemic normalization / anti-aging	68
7.3.9. Safety	68



7.3.10. Fast onset	69
7.3.11. No infusion	69
7.3.12. Dual mechanism of action.....	69
8. Coya Therapeutics	70
8.1. Coya 301's mechanism of action	70
8.2. Scientific background	70
8.3. Mechanistic similarities and differences	71
8.3.1. Anti-inflammatory activity through the modulation of Tregs	71
8.3.2. Potential to stabilize cognitive decline	71
8.3.3. Biomarkers.....	73
8.3.5. Safety.....	74
8.3.6. Fast onset	74
9. Risks.....	75
9.1. General	75
9.2. Risks with regards to NE3107 and BioVie.....	75
9.2.1. Lack of substantial evidence of selectivity and homeostasis	75
9.2.2. Divergence in treatment response between mild and moderate AD population	76
9.2.3. Pathway circumvention or receptor overstimulation over time	77
9.2.4. The risk of inhibiting TNF entirely	77
9.2.5. Trial design risks.....	77
9.2.6. Two treatment candidates and four targeted indications.....	79
9.3. Risks with regards to XPro and INmune Bio	79
9.3.1. Introduction.....	79
9.3.2. Litigational/regulatory risks.....	80
9.3.3. Pathway circumvention or receptor overstimulation over time	80
9.3.4. Two treatment candidates and several targeted indications	80
9.3.5. INmune Bio is earlier-stage in AD.....	81
9.4. Risks with regards to Simufilam and Cassava Sciences	81
9.4.1. Lack of substantial scientific publications.....	81
9.4.2. Lack of clarity of symptomatic and/or disease-modifying treatment	81
9.4.3. Pathway circumvention or receptor overstimulation over time	82
9.4.4. Litigation risks.....	82
9.4.5. Possible divergence in treatment response between the mild and moderate AD population	83



9.4.6. The risk of inhibiting TNF entirely	84
9.4.7. Trial design risks.....	84
9.4.8. Unique focus on Alzheimer’s disease	84
9.5. Risks with regards to Coya 301 and Coya Therapeutics	85
9.5.1. Lack of substantial scientific publications.....	85
9.5.2. Divergence in treatment response between mild and moderate AD population	85
9.5.3. Pathway circumvention or receptor overstimulation over time (low risk).....	85
9.5.4. Trial design risks.....	85
9.5.5. Coya may be considered early-stage	86
10. A focus on reported biomarkers.....	87
10.1. Introduction.....	87
10.2. Biomarker reporting from anti-amyloid antibodies and other approaches	89
10.3. A word on neurofilament light chain.....	94
10.3.1. Introduction.....	94
10.3.2. Neurofilament Light Chain as a diagnostic and treatment-predictive biomarker in neurological disorders	94
10.3.3. Neurofilament Light Chain in AD.....	94
10.3.4. NfL in other neurodegenerative diseases.....	95
10.3.5. Recent accelerated approval based on NfL reductions in SOD1-ALS	96
10.3.6. Reporting of neurofilament light in the treatment of different neurodegenerative diseases	97
11. Conclusion	98